By Rédaction Africa Links 24 with Lizzy Lawrence
Published on 2024-01-18 23:43:51
Timothy Stenzel, who led the Food and Drug Administration’s (FDA) office of in vitro diagnostics and was responsible for overseeing the regulation of Covid-19 tests during the chaotic early days of the pandemic, has retired from the agency as confirmed by the FDA on Thursday. Stenzel’s departure marks the end of his tenure as the federal regulator dealing with the challenges of Covid-19 testing.
In the early stages of the pandemic, Stenzel found himself caught in a turf battle between the Centers for Disease Control and Prevention (CDC) and the FDA over the regulation of Covid tests. Politico reported that at one point, the CDC made Stenzel wait at its facility overnight after he arrived for a meeting on Covid test development.
During this tumultuous time, test manufacturers rapidly introduced new Covid-19 screening products with limited data, as the virus was new and little was known about it. The FDA was also confronted with the oversight of lab-developed tests (LDTs), many of which fell into the category of Covid-19 PCR tests. Using powers granted by the public health emergency, the FDA required labs to apply for emergency use authorization. However, a STAT investigation revealed that the Department of Health and Human Services directed the FDA to stop this measure, despite knowing that many tests may have been inaccurate.
Stenzel’s retirement signifies the end of an era marked by regulatory challenges, bureaucratic clashes, and the FDA’s response to the rapid development and roll-out of Covid-19 tests. His departure leaves a vacancy in a critical position at the FDA, as the agency continues its work in overseeing diagnostic tests and navigating the evolving landscape of public health emergencies.
Read the original article on Africa Health News
